These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23273394)

  • 1. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
    Park KW; Lee JM; Kang SH; Ahn HS; Yang HM; Lee HY; Kang HJ; Koo BK; Cho J; Gwon HC; Lee SY; Chae IH; Youn TJ; Chae JK; Han KR; Yu CW; Kim HS
    J Am Coll Cardiol; 2013 Feb; 61(5):536-44. PubMed ID: 23273394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
    Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.
    Damman P; Abdel-Wahab M; Möllmann H; Richardt G; Chevalier B; Barragan P; Tijssen JG; Underwood P; Hamm CW
    J Invasive Cardiol; 2012 Oct; 24(10):495-502. PubMed ID: 23043032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
    Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
    J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
    JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
    JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of everolimus- and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease.
    Cho SC; Jeong MH; Kim W; Ahn Y; Hong YJ; Kim YJ; Kim CJ; Cho MC; Han KR; Kim HS;
    J Cardiol; 2014 Jun; 63(6):409-17. PubMed ID: 24314902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
    Sen H; Lam MK; Tandjung K; Löwik MM; Stoel MG; de Man FH; Louwerenburg JH; van Houwelingen GK; Linssen GC; Doggen CJ; Basalus MW; von Birgelen C
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):74-81. PubMed ID: 24585502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.
    Park KW; Chae IH; Lim DS; Han KR; Yang HM; Lee HY; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Jo SH; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Gwon HC; Jang YS; Kim HS
    J Am Coll Cardiol; 2011 Oct; 58(18):1844-54. PubMed ID: 22018294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.
    Chen KY; Rha SW; Wang L; Li YJ; Li GP; Poddar KL; Park JY; Choi CU; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
    JACC Cardiovasc Interv; 2012 Sep; 5(9):936-45. PubMed ID: 22995881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
    Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.